Recursion Pharmaceuticals' estimated fair value is US$14.64 based on 2 Stage Free Cash Flow to Equity Current share price of US$12.08 suggests Recursion Pharmaceuticals is potentially trading close to ...
One thing that stands out about Recursion right away is how the company refers to itself. Recursion doesn't say that it's a pharmaceutical, biopharmaceutical, or biotech company. Instead, it uses the ...
A recent JavaWorld Community forum message (Stack Overflow after instantiating new object) reminded me that the basics of the StackOverflowError are not always ...
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business. Together, the ...
SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback